tiprankstipranks
Trending News
More News >
Parenteral Drugs (India) Limited (IN:PDPL)
:PDPL
India Market
Advertisement

Parenteral Drugs (India) Limited (PDPL) Ratios

Compare
0 Followers

Parenteral Drugs (India) Limited Ratios

IN:PDPL's free cash flow for Q4 2021 was ₹<0.01. For the 2021 fiscal year, IN:PDPL's free cash flow was decreased by ₹ and operating cash flow was ₹10.84. See a summary of the company’s cash flow.
Ratios
TTM
Mar 22Mar 21Mar 20Mar 19
Liquidity Ratios
Current Ratio
0.06 0.06 0.07 0.08-
Quick Ratio
0.06 0.06 0.07 0.07-
Cash Ratio
<0.01 <0.01 <0.01 <0.01-
Solvency Ratio
-0.03 -0.08 -0.09 -0.08-
Operating Cash Flow Ratio
>-0.01 0.11 0.11 0.54-
Short-Term Operating Cash Flow Coverage
0.00 0.12 0.12 0.59-
Net Current Asset Value
₹ -12.41B₹ -11.83B₹ -10.46B₹ -9.20B-
Leverage Ratios
Debt-to-Assets Ratio
0.22 1.89 1.71 1.55-
Debt-to-Equity Ratio
-0.13 -1.57 -1.69 -1.88-
Debt-to-Capital Ratio
-0.15 2.76 2.46 2.14-
Long-Term Debt-to-Capital Ratio
-0.15 -0.05 -0.06 -0.08-
Financial Leverage Ratio
-0.59 -0.83 -0.98 -1.21-
Debt Service Coverage Ratio
0.66 0.02 0.01 0.02-
Interest Coverage Ratio
0.00 >-0.01 >-0.01 >-0.01-
Debt to Market Cap
9.99 114.10 122.05 34.99-
Interest Debt Per Share
71.58 401.47 354.21 313.91-
Net Debt to EBITDA
2.88 -91.52 -65.52 -51.71-
Profitability Margins
Gross Profit Margin
35.67%39.80%5.58%23.64%-
EBIT Margin
-33.89%-238.92%-132.30%-266.76%-
EBITDA Margin
438.65%-96.35%-60.10%-50.75%-
Operating Profit Margin
0.00%-0.24%-0.13%-0.27%-
Pretax Profit Margin
-1284.39%-1271.11%-589.95%-566.90%-
Net Profit Margin
-898.77%-1001.55%-474.81%-462.23%-
Continuous Operations Profit Margin
-898.77%-1001.55%-474.81%-462.23%-
Net Income Per EBT
69.98%78.79%80.48%81.54%-
EBT Per EBIT
0.00%530847.55%442488.33%209035.75%-
Return on Assets (ROA)
-15.77%-21.42%-20.67%-27.36%-
Return on Equity (ROE)
9.27%17.82%20.32%33.09%-
Return on Capital Employed (ROCE)
0.00%<0.01%<0.01%0.03%-
Return on Invested Capital (ROIC)
0.00%>-0.01%>-0.01%-0.02%-
Return on Tangible Assets
-15.77%-21.80%-21.04%-27.82%-
Earnings Yield
-711.39%-1295.87%-1471.48%-616.23%-
Efficiency Ratios
Receivables Turnover
0.00 1.29 0.00 0.00-
Payables Turnover
0.56 0.94 2.86 2.06-
Inventory Turnover
5.32 4.60 18.07 6.15-
Fixed Asset Turnover
0.04 0.04 0.07 0.09-
Asset Turnover
0.02 0.02 0.04 0.06-
Working Capital Turnover Ratio
>-0.01 -0.01 -0.03 -0.05-
Cash Conversion Cycle
-585.70 -28.27 -107.41 -118.03-
Days of Sales Outstanding
0.00 282.13 0.00 0.00-
Days of Inventory Outstanding
68.61 79.38 20.20 59.31-
Days of Payables Outstanding
654.31 389.78 127.61 177.34-
Operating Cycle
68.61 361.51 20.20 59.31-
Cash Flow Ratios
Operating Cash Flow Per Share
-0.16 42.03 37.69 159.99-
Free Cash Flow Per Share
-0.16 42.03 37.69 159.99-
CapEx Per Share
0.00 0.00 0.00 0.00-
Free Cash Flow to Operating Cash Flow
1.00 1.00 1.00 1.00-
Dividend Paid and CapEx Coverage Ratio
0.00 0.00 0.00 0.00-
Capital Expenditure Coverage Ratio
0.00 0.00 0.00 0.00-
Operating Cash Flow Coverage Ratio
>-0.01 0.12 0.12 0.57-
Operating Cash Flow to Sales Ratio
-0.06 10.31 4.68 14.91-
Free Cash Flow Yield
-4.50%1334.30%1449.43%1987.47%-
Valuation Ratios
Price-to-Earnings (P/E) Ratio
-0.14 -0.08 -0.07 -0.16-
Price-to-Sales (P/S) Ratio
1.26 0.77 0.32 0.75-
Price-to-Book (P/B) Ratio
-0.01 -0.01 -0.01 -0.05-
Price-to-Free Cash Flow (P/FCF) Ratio
-22.24 0.07 0.07 0.05-
Price-to-Operating Cash Flow Ratio
-22.24 0.07 0.07 0.05-
Price-to-Earnings Growth (PEG) Ratio
<0.01 -0.01 <0.01 >-0.01-
Price-to-Fair Value
-0.01 -0.01 -0.01 -0.05-
Enterprise Value Multiple
3.16 -92.32 -66.06 -53.19-
Enterprise Value
1.18B 10.81B 9.54B 8.64B-
EV to EBITDA
3.16 -92.32 -66.06 -53.19-
EV to Sales
13.88 88.95 39.70 27.00-
EV to Free Cash Flow
-244.32 8.63 8.49 1.81-
EV to Operating Cash Flow
-244.32 8.63 8.49 1.81-
Tangible Book Value Per Share
-276.32 -228.98 -188.21 -149.85-
Shareholders’ Equity Per Share
-276.36 -229.02 -188.25 -149.89-
Tax and Other Ratios
Effective Tax Rate
0.30 0.21 0.20 0.18-
Revenue Per Share
2.85 4.08 8.06 10.73-
Net Income Per Share
-25.61 -40.82 -38.26 -49.61-
Tax Burden
0.70 0.79 0.80 0.82-
Interest Burden
37.90 5.32 4.46 2.13-
Research & Development to Revenue
0.00 0.00 0.00 0.00-
SG&A to Revenue
0.00 0.08 0.04 0.05-
Stock-Based Compensation to Revenue
0.00 0.00 0.00 0.00-
Income Quality
<0.01 -0.81 -0.79 -2.63-
Currency in INR
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis